These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 25450208)
1. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. Ruane PJ; Ain D; Stryker R; Meshrekey R; Soliman M; Wolfe PR; Riad J; Mikhail S; Kersey K; Jiang D; Massetto B; Doehle B; Kirby BJ; Knox SJ; McHutchison JG; Symonds WT J Hepatol; 2015 May; 62(5):1040-6. PubMed ID: 25450208 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Foster GR; Pianko S; Brown A; Forton D; Nahass RG; George J; Barnes E; Brainard DM; Massetto B; Lin M; Han B; McHutchison JG; Subramanian GM; Cooper C; Agarwal K; Gastroenterology; 2015 Nov; 149(6):1462-70. PubMed ID: 26248087 [TBL] [Abstract][Full Text] [Related]
3. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. Doss W; Shiha G; Hassany M; Soliman R; Fouad R; Khairy M; Samir W; Hammad R; Kersey K; Jiang D; Doehle B; Knox SJ; Massetto B; McHutchison JG; Esmat G J Hepatol; 2015 Sep; 63(3):581-5. PubMed ID: 25937436 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Andrieux-Meyer I; Tan SS; Thanprasertsuk S; Salvadori N; Menétrey C; Simon F; Cressey TR; Said HRHM; Hassan MRA; Omar H; Tee HP; Chan WK; Kumar S; Thongsawat S; Thetket K; Avihingsanon A; Khemnark S; Yerly S; Ngo-Giang-Huong N; Siva S; Swanson A; Goyal V; Bompart F; Pécoul B; Murad S Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):448-458. PubMed ID: 33865507 [TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India. Shah SR; Chowdhury A; Mehta R; Kapoor D; Duseja A; Koshy A; Shukla A; Sood A; Madan K; Sud R; Nijhawan S; Pawan R; Prasad M; Kersey K; Jiang D; Svarovskaia E; Doehle B; Kanwar B; Subramanian M; Acharya SK; Sarin S J Viral Hepat; 2017 May; 24(5):371-379. PubMed ID: 27933698 [TBL] [Abstract][Full Text] [Related]
7. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Kao JH; Chien RN; Chang TT; Peng CY; Hu TH; Lo GH; Wang HY; Chen JJ; Yang JC; Knox SJ; Han L; Mo H; Mathias A; Brainard DM; Sheen IS; Hsu YC; Chu CJ; Chuang WL Liver Int; 2016 Aug; 36(8):1101-7. PubMed ID: 26835876 [TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z; Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043 [TBL] [Abstract][Full Text] [Related]
9. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110 [TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lawitz E; Poordad FF; Pang PS; Hyland RH; Ding X; Mo H; Symonds WT; McHutchison JG; Membreno FE Lancet; 2014 Feb; 383(9916):515-23. PubMed ID: 24209977 [TBL] [Abstract][Full Text] [Related]
11. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. Ahn SH; Lim YS; Lee KS; Paik SW; Lee YJ; Jeong SH; Kim JH; Yoon SK; Yim HJ; Tak WY; Han SY; Yang JC; Mo H; Mathias A; Han L; Knox SJ; Brainard DM; Kim YJ; Byun KS; Kim YS; Heo J; Han KH J Viral Hepat; 2016 May; 23(5):358-65. PubMed ID: 26864153 [TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259 [TBL] [Abstract][Full Text] [Related]
13. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Symonds WT; Hindes RG; Berrey MM N Engl J Med; 2013 Jan; 368(1):34-44. PubMed ID: 23281974 [TBL] [Abstract][Full Text] [Related]